ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1644

Longitudinal Trajectory Models to Assess Pain and Risk of Difficult-to-Treat Rheumatoid Arthritis

Misti Paudel1, Leah Santacroce2, Nancy Shadick3, Michael Weinblatt4 and Daniel Solomon5, 1Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham & Women's Hospital, Boston, MA, 4Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 5Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA

Meeting: ACR Convergence 2025

Keywords: Epidemiology, pain, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1633–1649) ARP Posters II: ARP Epidemiology & Public Health

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Prior studies have observed that patient-reported outcomes, such as pain, are risk factors for progression to difficult-to-treat RA (D2T-RA), a state of multi-treatment failure. However, the impact of longitudinal trajectories in pain on the risk of D2T-RA is not known.

Methods: We used data from the longitudinal Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study (BRASS) registry. Study participants included those who were not classified as having D2T-RA at baseline and had at least two assessments of pain on the MDHAQ pain scale questionnaire.  D2T-RA was defined using EULAR 2021 criteria and follow-up continued through earliest of either qualifying for D2T-RA or the last study visit. We modeled trajectories of pain using latent class mixed models in R, and evaluated random intercepts and/or slopes, link functions (linear, beta, quadratic splines), and 0-4 latent classes. We used BIC, entropy, and class membership to select the best fitting model. We evaluated the hazard of progressing to D2T-RA in extended Cox Proportional hazards models. Three sets of models were assessed, including pain measures only at baseline, the current pain level, and the pain trajectory. All models were adjusted for age and gender.   

Results: Our analyses included 1,458 (92% of 1,581 BRASS enrollees) with mean age of 56 years, 82% female, and 20% with early RA. Over a mean follow-up of 81 months, 196 (13%) developed D2T-RA. We identified three latent classes of pain trajectories during follow-up, described as moderate-increasing (42%), low-stable (47%), and low-resolving (11%) (Figure 1). Among patients who progressed to D2T-RA during follow-up, 68% followed a moderate-increasing pain trajectory; 31% a low-stable trajectory, and < 1% a low-improving trajectory. In contrast, among those who did not progress to D2T-RA, the distribution was 38% moderate-increasing, 49% low-stable, and 13% low-improving. In age and sex adjusted extended Cox proportional hazards models (Table 1) we observed that a five unit increase in baseline pain or current observed pain was associated with 8-12% increased hazards of progression to D2T-RA (HR=1.08 & 1.12), respectively. In a model that included predicted pain (per five-unit increase) based on latent classes we observed 24% increased hazards of D2T-RA (HR=1.24). Finally, in a model including pain trajectory categories, we observed a 3.1-fold increased hazards of D2T-RA for participants with a moderate-increasing pain trajectory and a 93% reduction in hazards (HR =0.07) for participants with a low-resolving pain trajectory, compared to participants with a low-stable trajectory.   

Conclusion: In this cohort of patients at risk of progression to D2T-RA, pain trajectories were stronger predictors than baseline, or current pain levels.  Future research should explore joint trajectory models to better account for uncertainty. 

Supporting image 1Figure 1. Latent Classes of Pain Trajectories in Participants with RA

Supporting image 2Table 1. Extended Cox Proportional Hazards for Progression to D2T-RA


Disclosures: M. Paudel: None; L. Santacroce: None; N. Shadick: Bristol-Myers Squibb(BMS), 5, Janssen, 5; M. Weinblatt: aclaris, 2, amgen, 2, anaptysbio, 2, Artiva Bio, 2, Biohaven, 2, Bristol-Myers Squibb(BMS), 2, 5, Canfite, 11, Curie Bio, 2, Deep Cure, 2, Eli Lilly, 2, Gilead, 2, Ignite, 2, Inmedix, 11, Janssen, 5, Janux Therapeutics, 2, Johnson and Johnson, 2, Lifordi, 2, Marvel Bio, 2, Matchpoint, 2, Merck/MSD, 2, Neutrolis, 2, Novartis, 2, Sana, 2, Santa Ana, 2, Sci Rhom, 2, scipher medcine corp, 11, SetPoint Medical, 2, Surf Therapeutics, 2, Thymmune, 2, Xencorp, 2, ZuraBio, 2; D. Solomon: Amgen, 5, CorEvitas, 5, GreenCape Health, 8, Janssen, 5, UpToDate, 9.

To cite this abstract in AMA style:

Paudel M, Santacroce L, Shadick N, Weinblatt M, Solomon D. Longitudinal Trajectory Models to Assess Pain and Risk of Difficult-to-Treat Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/longitudinal-trajectory-models-to-assess-pain-and-risk-of-difficult-to-treat-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/longitudinal-trajectory-models-to-assess-pain-and-risk-of-difficult-to-treat-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology